AnaptysBio (NASDAQ:ANAB) Releases Earnings Results, Beats Estimates By $1.95 EPS

AnaptysBio (NASDAQ:ANAB) issued its quarterly earnings results on Thursday. The biotechnology company reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.84) by $1.95, FiscalAI reports. The firm had revenue of $30.27 million for the quarter, compared to analysts’ expectations of $25.56 million. AnaptysBio had a return on equity of 112.00% and a net margin of 82.37%.

AnaptysBio Stock Performance

ANAB stock opened at $47.77 on Friday. The stock has a market cap of $1.43 billion, a P/E ratio of 325.13 and a beta of 0.70. The firm has a 50 day simple moving average of $50.01 and a 200 day simple moving average of $56.31. AnaptysBio has a 52 week low of $21.93 and a 52 week high of $72.36.

Insiders Place Their Bets

In other AnaptysBio news, Director Hollings Renton sold 5,000 shares of the stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $49.87, for a total value of $249,350.00. Following the completion of the sale, the director owned 10,995 shares in the company, valued at $548,320.65. This represents a 31.26% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 31.50% of the company’s stock.

Wall Street Analysts Forecast Growth

ANAB has been the subject of several recent analyst reports. Wolfe Research reiterated an “outperform” rating and issued a $78.00 target price on shares of AnaptysBio in a report on Monday, August 31st. TD Cowen cut their price target on shares of AnaptysBio from $75.00 to $70.00 and set a “buy” rating on the stock in a report on Tuesday, August 25th. Cantor Fitzgerald restated an “overweight” rating on shares of AnaptysBio in a research report on Tuesday, September 22nd. Weiss Ratings restated a “sell (e+)” rating on shares of AnaptysBio in a research report on Wednesday, November 4th. Finally, Scotiabank lowered shares of AnaptysBio to a “hold” rating and set a $70.00 price objective for the company. in a research note on Tuesday, August 25th. Twelve research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $75.67.

AnaptysBio Company Profile

AnaptysBio is a biotechnology company focused on developing antibody-based treatments for inflammatory and autoimmune diseases. Its research programs target immune pathways that may be involved in conditions with significant unmet medical needs. The company’s pipeline has included rosnilimab, an investigational antibody designed to activate the PD-1 pathway, and ANB032, an investigational antibody targeting BTLA. AnaptysBio has also developed imsidolimab, an antibody targeting the IL-36 receptor; global rights to that program were licensed to Vanda Pharmaceuticals.